Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RFL with free AI briefings, catalyst countdowns, and dilution alerts.

RFL · Rafael Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$22.1M Cash on Hand
8.5mo Cash Runway
Follow RFL by email Get an email when RFL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RFL, unsubscribe in one click. Privacy

📣 What RFL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Corticosteroid ASTHMA Phase 4 · NCT01089322 Completed
Ascorbic Acid Colonoscopy Preparation Phase 4 · NCT02073552 Completed
Polyethylene Glycol 4000 Colonoscopy Preparation Phase 4 · NCT02073552 Completed
Biperiden Brain Injury Traumatic Moderate Phase 3 · NCT04945213 Recruiting
Brazilian Green Propolis Extract (EPP-AF) Covid19 Phase 2/3 · NCT04480593 Completed
Autologous mesenchymal cells transplantation Spinal Cord Injury Phase 2 · NCT02574585 Unknown
Autologous thyTreg Heart Transplantation Phase 1/2 · NCT04924491 Recruiting
Infusion of bone marrow mononuclear cells. Chronic Hepatitis Phase 2 · NCT02171949 Unknown
intravenous treatment with EVs Severe Acute Respiratory Syndrome (SARS) Phase 1/2 · NCT06002841 Unknown
Plasma rich in growth factors (PRGF-Endoret) Infertility Phase 2 · NCT03387501 Completed
Propolis Period (Green Propolis 250mg/day) Chronic Kidney Disease Requiring Chronic Dialysis Phase 1/2 · NCT04072341 Completed
Multiple doses of anti-SARS-CoV-2 Convalescent… COVID-19 Early Phase 1 · NCT05595538 Completed

Also used in these trials (approved or third-party drugs, not RFL's own candidates): Nicotine, Varenicline, Filgrastim.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RFL holds $22.1M in cash and short-term investments (as of Jul 31, 2026) and burns about $7.8M/quarter from operations, an estimated runway of 8.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RFL files for a raise →

👥 Who Owns RFL

Insiders 100% Institutions (60 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Howard S Jonas
Exec Chairman, CEO & President, Director
Insider 15,042,008 15,042,008.00% 2026-07-29
Rafael Holdings, Inc.
10% owner
Insider 12,998,194 12,998,194.00% 2024-12-23
I9 Plus, LLC 5%+ holder (13D) 3,616,431 3,616,431.00% 2025-06-05
William Conkling
Chief Executive Officer · +7,847 options
Insider 564,455 564,455.00% 2025-03-25
N Scott Fine
Director
Insider 335,348 335,348.00% 2025-07-14
David Polinsky
Chief Financial Officer
Insider 292,839 292,839.00% 2026-10-25
Markus Sieger
Director
Insider 219,710 219,710.00% 2026-01-28
Michael J Weiss
Director
Insider 141,861 141,861.00% 2026-01-28
Stephen M Greenberg
Director
Insider 102,491 102,491.00% 2025-01-06
Mark N Stein
Director
Insider 50,845 50,845.00% 2026-01-28
John Goldberg
CHIEF MEDICAL OFFICER
Insider 50,000 50,000.00% 2025-01-13
Joshua M Fine
Chief Operating Officer · +24,558 options
Insider 9,380 9,380.00% 2025-09-03

Share count 100 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RFL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RFL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.